TD Cowen analyst Stacy Ku has maintained their bullish stance on KALV stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Stacy Ku has given her Buy rating due to a combination of factors including KalVista Pharmaceuticals’ impressive financial performance and strong market demand for their product, Ekterly. The company reported $13.7 million in revenue for the third quarter, significantly surpassing expectations and demonstrating effective execution following Ekterly’s recent approval.
The favorable reimbursement dynamics and high patient demand for Ekterly, an oral treatment option for hereditary angioedema (HAE), further support the Buy rating. The product’s convenience and efficacy have been well-received, with a substantial number of patients starting treatment and payors showing support for its chronic use. These factors, combined with the potential for achieving future sales targets, underscore the positive outlook for KalVista Pharmaceuticals.
According to TipRanks, Ku is a 4-star analyst with an average return of 13.1% and a 60.34% success rate. Ku covers the Healthcare sector, focusing on stocks such as LENZ Therapeutics, BioCryst, and KalVista Pharmaceuticals.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $39.00 price target.